LYON, France, Nov. 5, 2007 (PRIME NEWSWIRE) -- EDAP TMS S.A. (NasdaqGM:EDAP - News), the global leader in High Intensity Focused Ultrasound treatment of prostate cancer, announces that it has closed its capital raise with selected U.S. based qualified institutional buyers, pursuant to which the investors purchased US $20 million in Unsecured Convertible Debentures, convertible into EDAP's ordinary shares, to be delivered in the form of American Depository Receipts (``ADRs''). The Company expects this investment to fully fund EDAP's ongoing Phase II/III clinical studies of Ablatherm-HIFU at selected leading cancer treatment centers across the U.S. Eligibility criteria and center information can be found online at http://www.clinicaltrials.gov or at participating centers.
